DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser maintains a Neutral rating on Usana Health Sciences (USNA) and lowers the price target from $48 to $46.
May 07, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DA Davidson maintains a Neutral rating on Usana Health Sciences and lowers the price target from $48 to $46.
The adjustment in price target by DA Davidson reflects a recalibration of expectations for USNA's stock value, but the maintenance of a Neutral rating suggests that the analyst sees neither significant upside nor downside in the near term. This could lead to a neutral short-term impact on USNA's stock price as the market digests this new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100